PERK LABS INC.
Condensed Consolidated Interim Financial Statements
For the Three Months Ended February 28, 2022 and 2021
(Unaudited)
(Expressed in Canadian Dollars)
PERK LABS INC. | |
Condensed Consolidated Interim Financial Statements | |
For the Three Months Ended February 28, 2022 and 2021 | Page |
Condensed Consolidated Interim Statements of Financial Position | 3 |
Condensed Consolidated Interim Statements of Operations and Comprehensive Loss | 4 |
Condensed Consolidated Interim Statements of Changes in Equity | 5 |
Condensed Consolidated Interim Statements of Cash Flows | 6 |
Notes to the Condensed Consolidated Interim Financial Statements | 7 - 30 |
2
PERK LABS INC.
Condensed Consolidated Interim Statements of Financial Position (Unaudited)
(Expressed in Canadian Dollars)
As at
ASSETS Current
Cash and cash equivalents Amounts receivable Marketable securities (note 5) Inventory
Prepaid expenses and deposits Current portion of note receivableProperty and equipment (note 6) Marketable securities (note 5) Note receivable
Intangible assets Total assets
LIABILITIES Current
Accounts payable and accrued liabilities (note 16)
Current portion of lease liabilities (note 17)Lease liabilities (note 17)
Total liabilities
SHAREHOLDERS' EQUITY
Share capital (note 7) Reserves (notes 7 and 8) Deficit
Total shareholders' equity
Total liabilities and shareholders' equityGoing concern (note 2)
Commitments (note 17)
Subsequent events (note 19)
Authorized for issuance by the Board of Directors on April 28, 2022.
/s/ James Topham
(Unaudited) February 28 2022
$
788,179 $ 29,770
1,304,217 987,828
13,075 9,074
113,046 83,360
1,279 2,249,566
111,396 135,221
487,064 651,994
4,371 234 2,852,631
$
251,128 $ 302,110
104,450 99,702
355,578 401,812
29,046 56,964
384,624 458,776
36,447,467 36,359,451
5,943,939 5,883,976
(39,923,399)
2,468,007 2,725,748
$
2,852,631
/s/ Kirk Herrington
Director
November 30 2021
1,287,468 29,579
- 2,397,309
- - 3,184,524
(39,517,679)
$ 3,184,524
Director
3
The accompanying notes are an integral part of these condensed consolidated interim financial statements.
PERK LABS INC.
Condensed Consolidated Interim Statements of Operations and Comprehensive Income (Loss) (Unaudited)
(Expressed in Canadian Dollars)
Note(s)
Three Months Ended February 28 February 28 2022 2021
Revenue Cost of sales Gross margin (loss)
Operating expenses
Depreciation
General and administration Research and development Sales and marketing Share-based compensation
14
$
8,982 $ 15,373 3,030 18,558
5,952
(3,185)
6
23,825
16,922
9
277,387 272,551
10
202,954 168,644
11
105,787 162,381
7,8,16
66,888 288,381
Total operating expenses
676,841 908,879
Loss before other income (expenses)
Other income (expenses)
Foreign exchange (loss)
Gain on sale of property and equipment Gain on sale of marketable securities Government subsidies and grants Interest expense
Interest income
Unrealized gain (loss) on marketable securities
(670,889) (912,064)
(2,875) (4,220)
2,400
-
5 15 17 5
79,350 118,005
15,275 63,902
(5,978)
(9,248)
722
235
176,275 2,333,180
Total other income (expenses)
265,169 2,501,854
Net income (loss) and comprehensive income (loss) for the period
Net income (loss) per share
Basic
Diluted
Weighted average number of shares outstanding (basic)
Weighted average number of shares outstanding (diluted)
$
(405,720)
$ 1,589,790
$ $
(0.00) $ 0.01
(0.00) $ 0.01
183,480,976 161,772,594
192,946,373 170,680,141
4
The accompanying notes are an integral part of these condensed consolidated interim financial statements.
PERK LABS INC.
Condensed Consolidated Interim Statements of Changes in Equity (Unaudited)
(Expressed in Canadian Dollars)
Number of
SharesShare CapitalReserves
Deficit
Total Equity
Balance, November 30, 2021 Shares issued for cash Share issuance costs Shared issued for services Shares issued under RSU plan Share-based compensation Net loss for the period
182,313,919 $ 1,028,000 - 650,542 61,250 - -
36,359,451 $
51,400
(1,542)
31,233
6,925 - -
5,883,976 $ - - - (6,925) 66,888 -
(39,517,679) $ - - - - - (405,720)
2,725,748
51,400
(1,542)
31,233 -
66,888
(405,720)
Balance, February 28, 2022
184,053,711 $
36,447,467 $
5,943,939 $
(39,923,399) $
2,468,007
Number of
SharesShare CapitalReserves
Deficit
Total Equity
Balance, November 30, 2020 Shares issued for cash Share issuance costs Shared issued for services Stock options exercised Warrants exercised
Shares issued under RSU plan Share-based compensation Net income for the period
152,474,995 $
17,496,000 -
685,036
60,000
687,173
89,000 - -
33,568,508 $
5,518,697 $
(38,030,367) $ 1,056,838
1,833,947 - - 1,833,947
(65,530) - - (65,530)
56,253 - - 56,253
14,766 54,974 8,900 - -
(5,766) - 9,000
- - 54,974
(8,900) 288,381 -
- -
- 288,381
1,589,790 1,589,790
Balance, February 28, 2021
171,492,204 $
35,471,818 $
5,792,412
(36,440,577) $ 4,823,653
5
The accompanying notes are an integral part of these condensed consolidated interim financial statements.
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Perk Labs Inc. published this content on 29 April 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 29 April 2022 16:07:07 UTC.